A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

NCT05919680 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Intestinal Failure Associated Liver Disease

Interventions

DRUG: NST-6179 Part A
DRUG: NST-6179 Part B
OTHER: Matched Placebo

Sponsor

NorthSea Therapeutics B.V.